News
-
1 min
Preliminary Subchronic Toxicology Study Results Indicate iQ-007 Has Favorable Safety Profile
-
1 min
iQure Pharma Inc. Secures Private Investment of $100,000
-
2 min
iQure Pharma Inc. Announces Dr. Katrin Rupalla as the newest member of their Board of Directors
-
2 min
iQure Pharma Inc. announces the Appointment of Professor Thomas Rades as CMC Advisor
-
3 min
iQure Pharma Inc. Secures Additional Investment of $50,000
-
2 min
iQ-007: Confirmation of Safety Profile and Second Indication by NINDS (US)
-
3 min
iQure Pharma Inc. announces the Appointment of Dr. Joseph Wettstein, as Chief Scientific Officer
